Published in

Elsevier, Genetics in Medicine, 4(16), p. 338-346, 2014

DOI: 10.1038/gim.2013.141

Links

Tools

Export citation

Search in Google Scholar

Recommendations from the EGAPP Working Group: Does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes

Journal article published in 2013 by Jonathan S. Berg ORCID, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficient evidence to recommend prostate cancer antigen 3 (PCA3) testing to inform decisions for when to rebiopsy previously biopsy-negative patients for prostate cancer or to inform decisions to conduct initial biopsies for prostate cancer in at-risk men (e.g., previous elevated prostate-specific antigen test or suspicious digital rectal examination).